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PKC-I~I. Inhibitors of nitric oxide production did not promote sur- 
vival and an inhibitor of PKC-5 caused cell death on both poly- 
L-lysine and FN. PKC-I~I was noted to translocate from the cy- 
tosol to the particulate membrane after plating on poly-L-lysine 
and this translocation was inhibited by the addition of an antiox- 
idant. Time-course analyses implicated endogenous ROS pro- 
duction as a secondary messenger leading to PKC-I~I activation 
and subsequent chondrocyte cell death. Cell survival on poly-L- 
lysine was improved by 50% in the presence of oligomycin which 
suggested the electron transport chain of the mitochondria as a 
candidate for the production ROS. However, cell death on poly- 
L-lysine was not associated with DNA fragmentation or activation 
of caspase activity consistent with necrotic rather than apoptotic 
cell death. Significant ATP depletion was noted in chondrocytes 
on poly-L-lysine suggesting a potential mechanism for a switch 
from apoptosis (which requires energy) to necrosis. 
Conclusion:  These results support a novel mechanism for chon- 
drocyte death when matrix and growth factor signals are lost that 
includes increased ROS production and activation of PKC-I~I. The 
signaling was PKC isoform specific since PKC-5 inhibition re- 
sulted in cell death suggesting it is required for survival signaling 
whereas activation of PKC-I~I promoted chondrocyte cell death. 
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The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) 
was a randomized double-blind placebo (P)- and celecoxib (CE)- 
controlled trial of 1583 OA patients designed to evaluate the effi- 
cacy of glucosamine (G), chondroitin sulfate (CS), and combina- 
tion (G+CS) in improving osteoarthritis (OA) knee pain. We calcu- 
lated the sample size needed to declare as statistically significant 
the treatment effect sizes observed in GAIT for each active treat- 
ment group compared with placebo, assuming power of 90% and 
two-sided alpha of 5% for each comparison. Sample sizes re- 
quired for 1) the primary outcome measure, which classified pa- 
tients as a treatment responder if they had a 20% reduction in the 
Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC) summed pain subscale at the end of treatment com- 
pared with the baseline measurement, 2) response using the Out- 
come Measures in Rheumatology Clinical Trials -Osteoarthritis 
Research Society International (OMERACT-OARSI) criteria, 3) 
change in WOMAC pain from baseline to end of follow-up, 4) 
change in WOMAC function and 5) change in Health Assessment 
Questionnaire (HAQ) pain. We also assessed the influence of the 
placebo response rate and baseline level of pain on the required 
sample sizes. These results are shown in the table. 
For WOMAC Pain 20% Response and OMERACT-OARSI Re- 
sponse, sample sizes decreased as the placebo response rate 
decreased. Overall, sample sizes were smaller for patients with 
moderate-to-severe knee pain due to OA than for patients with 
mild pain. OMERACT-OARSI Response generally required the 
smallest sample sizes. 
When planning randomized clinical trials of OA treatments for 
knee pain, the OMERACT-OARSI responder criteria will yield 
smaller sample size requirements. In addition, it is important to 
consider the expected level of pain patients may report at study 
entry. 
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Aim of Study: Proteinase-activated receptors (PARs) represent 
a family of seven transmembrane domain G protein coupled re- 
ceptors. They are activated by a proteolytic leavage generating 
a tethered activating ligand at the N-terminus. Four members of 
this family have been identified, and named PAR-l, -2, -3 and -4. 
PAR-2 plays a role in both neurogenic inflammation and hyperal- 
gesia by promoting the release of substance R PAR-2 was also 
recently suggested to be involved in inflammation and to induce 
the synthesis of catabolic and inflammatory factors. Until now, 
little has been reported on the involvement of this factor in hu- 
man osteoarthritic articular tissues. In this study, we investigated 
Abstract A 15- Table 1. Sample Sizes 
CE vs. P G vs. P CS vs. P G+CS vs. P Placebo Response 
WOMAC Pain 20% Response 
All 992 6606 3570 2368 60.1% 
Mild Pain* 1318 27450 4278 68882 61.7% 
Moderate-to-Severe Pain# 458 808 2086 162 54.3% 
OMERACT-OARSI Response 
All 950 7544 2368 1360 56.9% 
Mild Pain* 1496 >100000 3222 7816 59.3% 
Moderate-to-Severe Pain# 332 372 1082 154 48.6% 
Change in WOMAC Pain 
All 2636 49668 >100000 2456 -86.1 
Mild Pain* 5416 5938 97228 41872 -75.6 
Moderate-to-Severe Pain# 492 1380 84296 154 -123.0 
Change in WOMAC Function 
All 1428 > 100000 81016 2262 -227.4 
Mild Pain* 2434 3590 30606 35496 -209.2 
Moderate-to-Severe Pain# 462 504 >100000 200 -291.6 
Change in HAQ Pain 
All 2546 91538 22886 1870 -16.6 
Mild Pain* 6334 8490 > 100000 6334 - 15.0 
Moderate-to-Severe Pain# 448 1320 1222 276 -22.1 
*Mild Pain: Summed WOMAC Pain Score of 125-300mm, #Moderate-to-Severe Pain: Summed WOMAC Pain Score of 301-400mm 
